Our Team

Roderick Wong, MD, serves as Managing Partner and Chief Investment Officer of RTW. Rod is responsible for managing the firm’s investments focused on innovative drug development. Prior to forming RTW, he was a Managing Director and sole Portfolio Manager for the Davidson Kempner Healthcare Funds. Before joining Davidson Kempner, Rod held various healthcare investment and research roles at Sigma Capital Partners and Cowen & Company.

Rod simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.

Rod has a keen interest in educating the next generation of life science entrepreneurs. He regularly sits on a variety of corporate boards. In addition, he serves on the board of Penn Medicine, as an Adjunct Associate Professor of Finance at NYU Stern, and as Chairman of the RTW Charitable Foundation.

Sabera Loughran, serves as Partner, Chief Operations Officer at RTW. Sabera is responsible for oversight of the firm’s operational activities.

Sabera has more than twenty years of operational, financial, and compliance experience. She has extensive experience working at both buy and sell side firms. Before joining RTW, Sabera served as Director of Finance and Chief Compliance officer at Prime Logic Capital. Prior to joining Prime Logic, Sabera spent several years at Buckingham Capital Management as an operations and client service executive. She began her sell-side career in the Asset Management Division of Goldman Sachs, serving as a team leader of the Client Reporting Team of Private Wealth Management, and as a fixed income portfolio administrator and performance analyst. Sabera started her career as an auditor at the Unit Investment Trust internship program of Deloitte and Touche. Sabera received a BBA in Accounting, Summa Cum Laude, from Baruch College.

Naveen Yalamanchi, MD, serves as a Partner and Portfolio Manager at RTW. Naveen is responsible for the firm’s medical technology investments. He has more than 15 years of healthcare investment and research experience. Prior to RTW, Naveen was Vice-President and Co-Portfolio Manager at Calamos Arista Partners, a position he held from 2012 to 2015. Before joining Calamos, he held various healthcare investment roles at Millennium Management and Davidson Kempner Capital Management, where he worked with Rod.

Naveen serves on the board of directors of Rocket Pharmaceuticals, and also as a board observer for Dermtech, Ancora Heart, and Magnolia Medical Technologies.

Naveen graduated Phi Beta Kappa with a BS in Biology from MIT, and received his MD from Stanford University. He completed his surgical internship at UCLA Medical Center.

Stephanie A. Sirota, serves as a Partner and Chief Business Officer at RTW Investments, LP (“RTW”), where she is responsible for strategy and oversight of the firm’s business and corporate development as well as strategic partnerships with counterparties including banks, academic institutions, corporations, investors, and NGOs. She leads the business team on various types of domestic and cross-border transactions and is also responsible for shaping the firm’s governance policies underscoring impact and sustainability.

Stephanie has fifteen years of deal experience in financial services. Prior to joining RTW, she served as Director at Valhalla Capital Advisors, a macro and commodity investment manager. Stephanie also worked in the New York and London offices of Lehman Brothers, where she advised on various Merger & Acquisitions, IPOs, and capital market financing transactions with a focus on cross-border transactions for the firm’s global corporate clients.

Stephanie graduated with honors from Columbia University and also received a Master’s Degree from the Columbia Graduate School of Journalism. She has contributed to Fortune Magazine and ABCNews.com.

She serves as a director of RTW Venture Fund Ltd; President of the RTW Charitable Foundation; and Co-Chairman of Council of the New York Philharmonic.

Gotham Makker, MD, serves as head of Strategic Investments at RTW Investments, LP (“RTW”). Gotham has more than 17 years of healthcare industry experience. Prior to joining RTW, Gotham served as CEO of Simran Investment Group, LLC, a privately held equity investment fund. Before Simran, Gotham was a healthcare portfolio manager and principal at Citadel Investment Group LLC, a position he held from 2002 to 2005. Prior to joining Citadel, Gotham served in various analyst roles at Oracle Partners LP, covering biotechnology and medical device sectors. He began his career on the life sciences investment banking team at Hambrecht & Quist.

Gotham serves on the board of directors of Rocket Pharmaceuticals.

Gotham received his MD from the University of Nebraska Medical School, and he completed the Sarnoff cardiovascular research fellowship at Columbia University, College of Physicians & Surgeons and at Harvard Medical School, Brigham & Women’s Hospital.

Peter Fong, PhD, serves as Senior Managing Director, Head of Company Creation at RTW Investments, LP (“RTW”). In this role, Peter leads the firm's biotech new venture creation efforts, including serving as ICEO of the companies formed in this process. Peter also supports several other strategic initiatives and activities for the firm.

Prior to joining RTW, Peter worked at Flagship Pioneering in Cambridge as a member of the innovation team. In this role he led the creation and multiple financings of four Flagship companies and served as ICEO of each of them.

Peter previously worked at Genentech in Oncology Business Development, where he helped build Genentech’s oncology pipeline through partnerships. Peter led multiple key transactions for Genentech, amounting to more than $300M in upfront payments.

Prior to joining Genentech, Peter held various roles within business and corporate development in the industry. He led the New Ventures and Business Development unit at Memorial Sloan-Kettering; co-founded Carigent Therapeutics, spun out of Yale University; and worked as a chemist at General Electric prior to his graduate studies.

Peter received a PhD degree in bioengineering from Yale University, where he subsequently was a Brown-Coxe Postdoctoral Fellow, and his BS in biochemistry from Indiana University.

Robert Aurigema, serves as the Chief Financial Officer at RTW Investments, LP (“RTW”). Robert is responsible for oversight of the firm’s financial and operating activities.

Robert has extensive management and leadership experience having spent over 25 years building, servicing and managing investment companies across almost all sectors, strategies and major geographies. Prior to joining RTW, Robert spent six years as Chief Operating Officer and Chief Financial Officer at Balyasny Asset Management, a global multi-strategy, multi-manager hedge fund. Prior to BAM, Robert was the Chief Financial Officer and Chief Operating Officer for Plural Investments, a multi-manager hedge fund that he helped launch. Robert started his buy-side career at SAC Capital, where he built and managed all middle and back office functions and teams globally as Director of Operations. Robert has also served as COO, CFO, and CCO of SECOR Asset Management, and Global Head of Operations at Avenue Capital Group. He began his sell side career as a vice president at Goldman Sachs in their Prime Brokerage Division. Robert started his career at Deloitte & Touche in their Financial Instruments and Strategies Division.

Robert received a BS in Accounting from Villanova University and is a licensed CPA. He holds certifications from University of Oxford in Executive Leadership and from the London School of Economics in Data Analysis.

Chris Seiter serves as the Chief Corporate Finance Officer at RTW Investments, LP (“RTW”). Chris provides structuring and transactional leadership for new ventures originated at RTW as well as royalty and alternative investments. Chris also provides oversight and support to the financial operations and business development of the newly formed ventures.

Prior to joining RTW, Chris served as Chief Financial Officer of two development stage biopharmaceutical companies, Trevi Therapeutics and Millendo Therapeutics. Before shifting to an operational role, Chris served as Managing Director and Head of Life Sciences Investment Banking at Bank of America Merrill Lynch where he focused on advising life sciences companies on transactions ranging from equity and debt financings to mergers and acquisitions. Chris served in the Navy as a Nuclear Submarine Officer for five years before beginning his investment banking career.

Chris received a BA in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Naval Nuclear Power School.

Alice Lee, JD, serves as Senior Counsel at RTW and has over a decade of experience advising life sciences companies in corporate and transactional matters. Prior to joining RTW, she most recently served as a senior associate in the Life Sciences practice at Ropes & Gray LLP. Prior to that, she worked in the Intellectual Property Transactions and Technology practice at Sullivan & Cromwell LLP, and she began her legal career in the Mergers & Acquisitions practice at Cravath, Swaine & Moore LLP.

Alice received her law degree from Columbia Law School, where she served as a Senior Editor of Columbia Law Review and was a Harlan Fiske Stone Scholar. She earned an MS from Stanford University in Computer Science (with an emphasis in Bioinformatics), completed two years of pre-clinical coursework at Stanford Medical School, where she was an M.D. candidate, and graduated Phi Beta Kappa and summa cum laude with a BA in Philosophy from Columbia University. Prior to law school, Ms. Lee worked as a computational biologist at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida and co-authored “The promise of gene signatures in cancer diagnosis and prognosis” included in the Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics and “Fundamentals of Cancer Genomics and Proteomics” included in Surgery: Basic Science and Clinical Evidence. She also worked as a software development engineer intern at Amazon.com.

Dar Patel serves as the Chief Compliance Officer of RTW. He is responsible for oversight of  the firm’s compliance program. Dar has extensive legal and compliance experience that spans 20+ years in various capacities for multiple of investment advisers.  Prior to joining RTW, He was the General Counsel and Chief Compliance Officer at Assurant Investment Management, the third-party investment management arm of Assurant, Inc.     Before joining Assurant, Dar held multiple legal and compliance roles at Resource America, Inc., a multi strategy, multi-manager asset management firm, including Chief Compliance Officer, Chief Legal Officer of various operating subsidiaries and President and Chief Compliance Officer of Resource Securities, the broker dealer arm of Resource America.  Dar started his legal career as a litigation associate at multiple law firms, including Berman, Paley, Goldstein & Kannry.

Dar received a BA in Philosophy and Political Science from Boston University and a JD from The Washington College of Law at American University.

Nate Pelsma serves as the Chief Operating Officer for the RTW Foundation and the Managing Director for Communications and People for RTW Investments where he is responsible for the operations of the Foundation and leading communications and organizational development initiatives for RTW.

Prior to RTW, Nate spent the past ten years as CFO and COO of JMG, a youth workforce development organization, and Teach Plus, a national teacher leadership organization. He taught for eight years as an adjunct professor of nonprofit management at the Carroll Graduate School of Management at Boston College. Prior to working at Teach Plus, he was an economist for Analysis Group. Nate started his nonprofit career at City Year where he managed national corporate partnerships. In addition, prior to joining the RTW team, Nate served as an independent board director for RTW’s private funds. Nate has an MBA from Boston College and a BA in English from the University of Kansas.

Deborah serves as Executive Director of RTW Charitable Foundation and is responsible for leading the foundation and executing on its strategic mission to improve opportunities for all people to live healthier, longer lives.

Prior to joining RTWCF, Deborah Slipetz was at Merck and has 30 years of experience as a drug hunter scientist and executive leader in the pharmaceutical industry. She was part of the team that invented SingulairTM for asthma and has brought an additional 25 drug candidates into clinical trials. Deborah has broad depth and breadth of experience in drug discovery across multiple therapeutic areas. She recently served as Executive Director In-Vivo Pharmacology responsible for cardiovascular, diabetes, neuroscience, infectious diseases, respiratory, immunology and oncology therapeutic areas. Her core biology expertise lies within the respiratory and immunology area, where she held the position of therapeutic area lead.

Deborah most recently co-founded and served as the executive director of imagine@Merck, a transformative innovation engine that attracts thinkers and doers who seek to challenge the status quo by providing the framework to unleash and amplify their ingenuity to amplify change. This business unit served as a platform for employees to communicate and collaborate to drive change and identify solutions to pressing issues not only in drug development, but enterprise-wide. Her team was recognized by “Fast Company” in 2020 as one of the most “Innovative Teams”.

Deborah has a B.Sc. in cell and molecular biology, a M.Sc. in molecular genetics and a Ph.D. in pharmacology, all from McGill University, Montreal, Canada.

Joshua Kennedy-Smith, PhD, serves as a Managing Director, Research Analyst at RTW, where he specializes in the chemistry of small and large molecules, intellectual property, as well as leads our efforts in particular disease and technology areas. Josh also leads RTW’s internship and outreach programs.

Josh has more than a decade of professional experience in the pharmaceutical industry as both a research scientist and manager. Prior to joining RTW, he served as Principal Scientist and Head of Externalization at Schrodinger. Josh has experience in the area of inflammation and autoimmune disease, and served as a key contributor on a number of kinase inhibitor programs still in development. He began his career at Roche as a medicinal chemist working on the team that discovered the drug Elpida (elsulfavirine) for HIV.

Josh received a PhD in Chemistry from University of California, Berkeley and a BS in Chemistry from University of California, Santa Cruz and appears as an author and inventor on over 35 publications and patents. He has worked globally at sites in the US, Switzerland and India.

Piratip Pratumsuwan, serves as a Managing Director, Research Analyst at RTW, where he is responsible for conducting research in specific technology areas for the firm. In particular, Piratip leads RTW’s comprehensive effort in gene therapy and gene editing, which spans across public and private companies as well as within academic institutions.

Piratip joined RTW directly from academia in 2014. He received an MA in Biotechnology from Columbia University, and a BS in Biochemistry from McGill University.

Tony Nguyen, serves as a Managing Director, Research Analyst at RTW, where he leads commercial analysis of biopharma and medical technology assets. He is also the founding member of the firm’s internal Valuation Committee.

Tony’s focus on the commercial viability of new drugs and technologies is a critical component of RTW’s work. We are living in an age where diseases are being redefined based on their genetic causes, and it is of paramount importance to understand the changing opportunity set of addressable patients across diseases.

Tony received a BS in Electrical Engineering from the National University of Singapore and an MBA from St. John’s University, both on full academic scholarship.

Nehal Gosalia, PhD, serves as Associate Director of Genetics at RTW Investments, LP (“RTW”), where she is expanding ongoing research efforts using genetic data and bioinformatics tools.  Prior to joining RTW, Nehal spent four years at the Regeneron Genetics Center, where she utilized bioinformatic and computational tools to interrogate large exome sequencing datasets associated with phenotypic data, including electronic health records, to address questions on how human genetic variation contributes to disease. During her time at Regeneron, Nehal co-authored six publications, including high profile publications in Science and the New England Journal of Medicine.

Nehal has a PhD in Molecular Biology and Genetics from Northwestern University and a BS in Biology with a minor in Business from the Illinois Institute of Technology.

Brad Sitko serves as Managing Director of Strategic Finance at RTW Investments, LP (“RTW”). Brad is responsible for providing leadership and execution across the firm's key initiatives across new company formation, private transactions, business and corporate development and partnering, and the venture fund.

Brad brings over 15 years of 'swiss army knife' experiences to RTW including corporate strategy, business development, capital raising and M&A in life sciences and digital health. He has worked as a growth stage company executive, investment banker and strategy consultant. Before joining RTW, Brad led DNAnexus’ finance and operations teams as the company scaled its industry leading, cloud-based genomics IT platform. Prior to DNAnexus, Brad was a senior investment banker at MTS Health Partners executing more than 30 transactions accounting for $7B of M&A volume, capital raised and royalties monetized. Prior to joining MTS, Brad worked in corporate development and strategic planning at Pfizer. He began his career as a strategy consultant at Frankel Group, he advised biopharma companies on strategic planning, commercialization and market development strategies.

Brad received a BA in Bioethics from University of Pennsylvania and an MBA from Columbia Business School, with dual concentrations in Finance and Healthcare & Pharmaceutical Management.

Paul Lu, PhD, serves as Managing Director, Head of Business Development at RTW Investments. He helps drive partnering, business development, and strategic transactions for RTW and its portfolio companies.

Prior to joining RTW, Paul was Global Head of Business Development & Alliances at Hansoh Pharma, responsible for expanding innovative pipeline through partnerships and broadening ex-Asia footprint, for which he built and led Hansoh’s U.S. discovery research site. Before Hansoh, he led Global Business Development at Hengrui Medicine, overseeing licensing, alliances, M&A, and strategic investment into novel antibody platforms. He launched an R&D Center in Boston for Hengrui to pursue the discovery of first-in-class therapeutics. Earlier in his career he advised pharmaceutical, biotech, and healthcare services companies as a member of Lazard’s healthcare investment banking group, executing over $85 billion in complex M&A transactions, involving cross-border, shareholder activism, and restructuring situations.

Paul was a co-founder and President of The Biotechnology and Life Sciences Advising (BALSA) Group, a nonprofit consulting organization based in St. Louis, which established The BALSA Foundation to fund, support, and empower first-time entrepreneurs.

Paul received an MBA from Harvard Business School, where he was a Robert S. Kaplan Life Sciences Fellow, a PhD in Neuroscience from Washington University in St. Louis, and a bachelor’s degree from University of Waikato in New Zealand.

Sebastian Trousil serves as Principal, New Ventures, at RTW. In this role, Sebastian is responsible for conceptualizing, forming, and building best-in-class new ventures originated by RTW.

Prior to joining RTW, Sebastian worked at Flagship Pioneering as a member of the innovation team. Sebastian created three early-stage biotech companies; developed their scientific and corporate strategies; and led the operations of these companies as they scaled.

Sebastian completed his postdoctoral research at Harvard Medical School and the Massachusetts General Hospital, where he led multiple cancer research projects and was awarded the prestigious MGH Tosteson Fellowship. Sebastian received his PhD in Cancer Pharmacology from Imperial College London, UK, where he developed novel cancer drugs and molecular imaging modalities. One molecule he developed at Imperial College London has progressed into clinical trials. Sebastian holds a master’s degree in Pharmacy from the University of Vienna in Austria.

Shalini Sinha joins RTW as the Senior Director of Human Resources. She is passionate about driving business outcomes through strategic HR initiatives and has a successful track record of building HR infrastructures for start-ups and transforming companies.

Shalini was formerly the Executive Director and Head of HR Strategy at Sumitovant Biopharma. Prior to that, Shalini served in various HR positions at companies including Roivant, Apollo Global Management, and Goldman Sachs.

Shalini holds a BA from Rutgers University with concentrations in HR Management and Entrepreneurship. She has an advanced certified personal and executive coaching certification with the College of Executive Coaching and is a certified practitioner of the MBTI Step 1 and Step 2 Instruments.

Abdi Moazami serves as the Director of Compliance at RTW. He handles many of the day-to-day functions of the compliance program and works with our Chief Compliance Officer in the creation, implementation, oversight, and enforcement of RTW’s Compliance Manual and related policies and procedures. Abdi brings over 20 years’ experience in compliance management and investment consulting.

Prior to joining RTW, Abdi was the Compliance Manager at Clayton, Dubilier, & Rice, a private equity firm based in New York. Before joining CD&R, Abdi was an Associate in the Investment Consulting division of Rogerscasey. Abdi holds a BA in Economics from NYU.

Chris Liu, PhD, serves as a Senior Analyst at RTW, where he is responsible for oncology research as well as coverage of life sciences companies in China. Prior to joining RTW, Chris spent 5 years in Business Development at GenScript, where he primarily worked on antibody drug discovery and development including novel immuno-oncology targets. He also worked on the design and optimization of CAR constructs for CAR-T companies such as Kite, Juno, and Bellicum. Chris received a PhD in Biochemistry from SUNY Stony Brook and a BS in Chemistry from Fudan University. He also received his MBA in Finance and Management from NYU Stern School of Business.

Ovid C. Amadi, PhD, serves as a Senior Analyst at RTW Investments, LP (“RTW”) where he is responsible for coverage of medical technology companies including medical devices, life science tools, diagnostics, and digital health.

Prior to joining RTW, Ovid was a Principal at Boston Consulting Group where he spent six years advising medical device companies, biopharmaceutical companies, and government institutions (including the Centers for Medicare and Medicaid Services) on strategic and operational initiatives spanning M&A transactions, supply chain management, and organizational effectiveness.  Ovid spent a year seconded to the World Economic Forum where he co-led the Value in Healthcare initiative in partnership with healthcare CEOs and public officials around the world.

Ovid received a PhD in Medical Engineering and Medical Physics from the Harvard / MIT Division of Health Sciences and Technology, where he developed microfluidic applications in developmental biology and regenerative medicine.  He also has a BS in Mechanical Engineering from MIT.

Lauren Cuje serves as a Venture Senior Associate at RTW Investments, LP (“RTW”), where she is responsible for expanding the fund’s research interests in new disease areas, as well as supporting efforts around new company formation.

Prior to joining RTW, Lauren worked as a consultant to the life sciences industry and within the asset management division of Goldman Sachs. Lauren received a MA in Biotechnology from Columbia University and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado.

Connor Williams, serves as an Analyst at RTW, where he is responsible for research in neurological disease. Connor is also actively involved in RTW’s efforts to better understand genetic drivers of disease more generally. Connor has experience as a lab researcher at The University of Hong Kong and contributed to a published work during his tenure at HKU. Connor received a BA in Biology and Psychology, and a MA in Psychology with a focus on Biopsychology from NYU.

Mirabelle brings over 14 years of consulting experience where her focus has ranged from launch strategy and commercialization issues in China, specializing in pricing and market access strategy, and new product commercial and opportunity assessment. Mirabelle was most recently with IQVIA as a Principal, Management Consulting, and previously an Associate Director with Navigant Consulting (Guidehouse) Life Science.

Mirabelle studied in Ecole Supériere de Commerce Montpellier, France, she holds dual bachelor’s degrees in economics and business. She also studied psychology at Peking University Medical School.

Steven B. Saland, MD, serves as Research Specialist at RTW, where he is responsible for enhancing the RTW research process related to the collection, organization, and analysis of data.

Steve graduated with a BS in Archaeology from Columbia University, and has traveled extensively throughout Western Europe, Central America, Sub-Saharan Africa and the Middle East to visit old excavation sites and sometimes participate in active archaeological digs. Steve received his medical degree from the University of Pennsylvania School of Medicine and has trained in Anesthesiology and Critical Care.

Jennifer Aoki serves as Research Specialist at RTW Investments, LP (“RTW”). Prior to joining RTW, Jenn served in various roles at Blackstone, first as an Executive Assistant in Private Equity and later as Life Sciences Coordinator.

Jenn received her Master’s degree from Columbia University where she was a PhD Candidate in Biochemistry and Molecular Physics.  She has over a decade of research lab experience at Columbia University, Caltech, UCSF, and CSULA in both Molecular Biology and Organic Chemistry.  She graduated from California State University Los Angeles with a B.S. in Biochemistry.

James Bellush, PhD, serves as a Venture Associate at RTW, where he is responsible for conducting research on novel genetic targets in several disease areas. Prior to joining RTW, James was a Research Fellow at Memorial Sloan-Kettering Cancer Center, where he developed genome sequencing and bioinformatics platforms to study how gene regulatory elements control transcription during animal embryogenesis.

James has a PhD in Biochemistry and Molecular Biology from Weill Cornell Graduate School of Medical Sciences and a BS in Biology from Moravian College.

Biming Wu, PhD, serves as a Research Associate at RTW Investments, LP where he conducts scientific and commercial analysis of medical technology assets. Prior to joining RTW, Biming was a research fellow at the Regeneron Genetics Center. His research focused on developing algorithms and building machine learning tools to analyze large-scale biomedical datasets and aid drug discovery.

Biming received a PhD in Biomedical Engineering from the University of Michigan, where he developed synthetic biology tools and biomaterials for orthopedic applications.  He also has a BS in Chemical Engineering from the University of Iowa.

Yuantao Li, PhD, serves as a Research Associate at RTW, where he supports the firm’s coverage of life science companies in China.  

 Prior to joining RTW, Yuantao was a Senior Life Science Specialist at L.E.K. Consulting, where he advised top-20 large pharmaceutical companies, leading biotech firms, banks and investment firms on corporate strategy, BD strategy, and due diligence for transactions. Prior to L.E.K., he worked briefly at Boehringer Ingelheim where he participated in the development of a novel process that facilitates downstream drug formulation. Yuantao received a PhD degree in chemistry from New York University and a BS degree in chemistry from Nanjing University.  

Lauren Lee, PhD, serves as a Research Associate at RTW, where she is responsible for covering oncology research. Prior to joining RTW, Lauren was on the investment team at Solasta Ventures and subsequently, at Syno Capital, where she held roles in sourcing, diligence, and leading investments in venture stage opportunities in therapeutics.

Lauren received her PhD in Oncology from the Johns Hopkins University School of Medicine, where she was involved in the development of small molecules for acute myeloid leukemia in collaboration with Astellas and Daiichi Sankyo. During this time, she also served as the Head of Strategy at Aidar Health, a medical technology start-up in the Baltimore area. Prior to these roles, Lauren started off her career as a bench scientist in the Translational Biology group at Onyx Pharmaceuticals and Amgen in South San Francisco, where she was focused on immunoproteasome research. She also holds BA and BS degrees in Immunology and Economics from the University of California, Berkeley.

Stefan Prendergast serves as a Research Associate at RTW Investments, LP where he conducts scientific and commercial analysis of medical technology assets. Before joining RTW, Stefan was a Life Sciences Consultant at L.E.K. Consulting in London and New York where he led strategic engagements for medtech, biopharmaceutical, and healthcare clients as well as leading investment firms. At L.E.K., his project experience encompassed commercial opportunity assessments, M&A advisory, innovation and growth strategy, and R&D portfolio prioritization.

Stefan holds an MSc in Biochemistry and Molecular Biology with a focus on cancer biology from Johns Hopkins Bloomberg School of Public Health and a BS in Biological Sciences from the University of Notre Dame.

Irene Park, serves as a Biotechnology Research Assistant at RTW, where she is responsible for supporting research across therapeutic areas, with a focus on commercial analysis. Prior to joining RTW, Irene was a consultant at Deloitte where she advised senior-level clients in biotech, pharma, provider, and retail healthcare industries.

Irene is a graduate of the Roy and Diana Vagelos Program in Life Sciences and Management at the University of Pennsylvania, where she received a BA in Biology and a BS in Economics from the Wharton School.

Sabrina Xiao, serves as Research Assistant at RTW Investments, LP working along the Research Team to gather and curate medical and scientific data. Prior to RTW, Sabrina served as both a Research Coordinator at the Simons Foundation where she supported external research projects from drafting participant materials to recruiting with the Research Match program. She also facilitated researcher access to datasets across SFARI Cohorts.

Sabrina holds a B.S. in Biochemistry and Molecular Biology from University of Miami.  She was a recipient of the Stamps Scholarship, UM's most prestigious merit award.

Michelle Krinke, serves as Head Trader at RTW. Michelle has ten years of experience in financial services. Prior to joining, she worked at Sio Capital as the Director of Marketing.

Earlier in her career, Michelle worked as a fund accountant at Meridian Fund Services and in a sales role at Bloomberg LP. Michelle received a BA from the University of Texas at Austin and was awarded a full athletic scholarship for tennis.

Matthew Bieret serves as the Senior Director of Finance at RTW Investments, LP and has more than 15 years of experience in accounting and auditing within the financial services industry.  Prior to joining the Firm, Matthew worked at York Capital Management most recently serving as Senior Vice President, Co-Head of Fund Accounting.  There he oversaw the day-to-day fund accounting function and was a member of York’s Operating and Valuation Committees.  Prior to joining York, he worked as a senior auditor in the Financial Services Group of Ernst & Young LLP.  Matthew received a B.S. in Accounting and a M.S. in Accounting from Rider University and is a licensed Certified Public Accountant.

Mike Christman, serves as Senior Director of Operations at RTW. Mike has more than a decade of accounting and operations experience in financial services. Prior to joining RTW, he worked at Atlantic Investment Management, Inc., serving as Assistant Controller. Before joining Atlantic, he served as senior fund accountant at Bellman Walter Capital, LLC. Mike began his career as an auditor at Pricewaterhouse Coopers. Mike received a BBA from the University of Massachusetts at Amherst.

David Moore, serves as Controller at RTW. David has over fifteen years of accounting, audit and fund administration experience. He previously worked at SS&C Technologies, Inc., as Director in their Fund Services division. Earlier in his career, David worked as a senior financial analyst at The Blackstone Group, L.P. and as a financial services associate at Arthur Andersen LLP. David is a licensed CPA in the State of New York, received an MBA from New York University and graduated summa cum laude with a BS in Accounting from CUNY Brooklyn College.

Krisha McCune, serves as Director of Client Service and IR at RTW. Prior to joining, Krisha was an auditor in public accounting at RubinBrown, LLP. Krisha is a licensed CPA, received an MBA from Lindenwood University, and graduated with a BA in Chinese from Duke University.

Alexandra Taracanova, PhD, serves as Director of Investor Relations at RTW, where she is responsible for the development and execution of the Investor Relations program for the RTW Venture Fund.  Prior to joining RTW, Alexandra served as Medical Science Liaison at Advanced Accelerator Applications (“AAA”), a Novartis Company, where she led clinical oncology research collaborations and was responsible for medical affairs strategy execution. Prior to joining AAA, Alexandra was a Life Science Specialist at LEK Consulting, where she provided consulting services to biopharmaceutical and medical technology clients.

Alexandra received her PhD in Pharmacology and Experimental Therapeutics from Tufts University School of Medicine. She was recognized as Dean’s Fellow for her academic achievements and her thesis work was published in Proceedings of the National Academy of Sciences. While in graduate school, Alexandra served as a Business Development Associate at MPM Capital in Cambridge, MA. Alexandra graduated summa cum laude with Bachelor of Science in Biochemistry from State University of New York Plattsburgh.

Lorrie Nathan, CPA, serves as Director of Valuations at RTW. She previously worked at Alvarez & Marsal, LLC, as a Manager in the Valuation Services group. Prior to Alvarez & Marsal, Lorrie was a Vice President at Citi where she worked in the Citi Treasury Investments Controllers group. Earlier in her career, she worked as an auditor at Ernst & Young LLP and EisnerAmper LLP.

Lorrie is a licensed CPA in the State of New York, holds a BBA in Accounting from the University of Wisconsin-Madison, and a MS in Finance from Baruch College.

Michael Davidson serves as Director of Tax at RTW Investments, LP (“RTW”), where he is responsible for a variety of tax work related to specific investments, the RTW funds, and RTW principals.  Prior to joining RTW, Mike worked at Chilton Trust, a premier wealth management company that provides wealth management services and investment solutions to high net worth individuals, families, foundations, endowments and institutions.  Prior to joining Chilton, Mike worked at Aprio, the largest independent CPA-led business advisory firm based in Atlanta.

Mike graduated from Kennesaw State University with a Bachelor’s Degree in Accounting.

Daniel Heuser serves as the Director of Technology. Prior to RTW, Daniel worked at Serengeti Asset Management, an investment firm with a focus on niche credit opportunities as the Manager of Technology. Daniel began his career in finance as an Infrastructure Engineer at Folger Hill Asset Management where he helped with the launch of the firm. Daniel received his degree in Information Technology from New York Institute of Technology.

Deirdre is the Director of Business Administration at RTW.  She comes to RTW from Rocket Pharmaceuticals where she was a founding team member responsible for the development of the G&A infrastructure as well as managing key relationships for the CEO. Most recently, she was responsible for the design, construction and build out of Rocket’s state of the art Manufacturing and R&D facility before returning to RTW to assist with their continued organizational growth.

Deirdre was a member of the Goldman Sachs 2015 Returnship program and began her career as a marketing associate in the Fixed Income Division of Morgan Stanley.  She has been actively engaged in the non-profit sector addressing the unmet needs of families for the last 30 years.  Deirdre received her BA in Management from Gettysburg College.

Gregory DiBella, JD, serves as Associate Counsel at RTW. Prior to joining RTW, Greg was a managing associate in the Venture Technology and Emerging Growth Companies practice at Dentons US LLP. Greg completed a secondment at Apollo Global Management, where he advised private equity investment teams across multiple verticals on matters ranging from evaluation of targets to integration of new portfolio companies. He began his legal career in Mergers & Acquisitions at Paul, Weiss, Rifkind, Wharton & Garrison LLP.

Greg received his law degree from Georgetown University Law Center, and his AB magna cum laude and Phi Beta Kappa in Government and Philosophy from Harvard College. His prior experience includes working for a Latin American-focused trading desk, interning for FINRA and the US Treasury and preparing a Harvard Business School case study, "The Struggle Over Public Education in Early America," Case No. 713-077.

Julia Enright, serves as a Senior Associate of Business Development at RTW. Julia serves on RTW’s business team and contributes to various efforts, including capital raising, counterparty relationships, impact initiatives, and content production. Prior to joining RTW, Julia spent three years as a healthcare investment banking analyst at Canaccord Genuity Group and Janney Montgomery Scott. Julia received her BBA from Villanova University.

Ryan Sherman, CPA, serves as Assistant Controller at RTW. He previously worked as an Associate Vice President at Ares Management in the Alternative Credit Group where he was responsible for both accounting and financial reporting. Prior to Ares Management, Ryan worked as an Alternative Investments Audit Manager at PricewaterhouseCoopers, focusing on both hedge and private equity funds. Ryan is a licensed CPA in the State of New York and holds a BS in Accounting from the University of Connecticut.

Chris Krone, CPA, serves as Family Office Senior Associate at RTW Investments, LP where he is responsible for a variety of tax and estate planning work. Prior to joining RTW, he worked at Goldman Sachs - Ayco Personal Financial Management as a Financial Planner providing wealth management services to high-net-worth individuals and their families. Before that, he began his career at KPMG LLP as a tax associate in their Global Mobility Services practice.

Chris is a licensed CPA in the State of New York and holds a BS and MS in Accounting from Binghamton University.

Maria Aronov serves as an Operations Associate at RTW Investments LP, (“RTW”). Prior to joining RTW, Maria was an associate at Three Bridges Capital, a hedge fund specializing in international equities. Before joining Three Bridges, she held various internships at UBS, Skybridge Capital, and NetSuite.

Maria graduated with a BS in Finance from Bentley University.

Jamie Lynne Sullivan, serves as Executive Assistant and Business Administrator to the Partners at RTW Investments, LP. Prior to joining RTW, Jamie spent one year working as Executive Assistant for a software focused technology startup company. Prior to her move to a more corporate role, Jamie spent a decade working as a theatrical stage manager and on various film and television projects in New York City and Cincinnati, OH. Jamie graduated with a Bachelor of Fine Arts from Western Kentucky University.

Lindsay McBride serves as the Executive Assistant to the MedTech Research Team at RTW Investments, LP. Prior to joining RTW, Lindsay spent four years supporting executives within two Alternative Asset Management firms. Before her career in financial services, Lindsay worked in education as an Elementary School Teacher and a member of the Intervention & Referral Service Board.  Lindsay earned her Bachelor of Science in Elementary Education from West Chester University.

Jennifer Williams serves as the Executive Assistant to the Chief Business Officer at RTW Investments, LP. Prior to joining RTW, Jennifer spent six years in various roles within Business Development and Investor Relations at Folger Hill Asset Management and Schonfeld Strategic Advisors. Previous to her career within financial services, Jennifer spent a decade working in marketing and design.

Jennifer holds degrees in Marketing and International Relations from Indiana University and Interior Design from the Fashion Institute of Technology.

Kaitlin Cusano joins us an Executive Assistant for the Fund Services team supporting the COO, CFO, and CCO.

Previously, Kaitlin was at Kushner Companies where she spent the last 5 years as an EA/ PM to the CEO, COO and Director of Development overseeing the day-to-day operations and tasks for the C-Suite Management team as well as the Kushner Family. Prior to Kushner Companies, Kaitlin held positions at Prudential Realty, JP Morgan, and Glamourpuss NYC. Kaitlin has a BA in History & Art History from University of Vermont.